Scouting, Investing in and Nurturing Healthcare Innovation
NOCTURNAL LABS TEAM
Nocturnal Labs team is led by a group of senior professionals with diverse backgrounds in industry, science and finance. The team’s complementary backgrounds give Nocturnal Labs a unique strategic perspective on the key players, events, and forces shaping the life science industry, and allow the company to identify investment opportunities minimizing the associated risks.
Working as a real partner with the selected companies, Nocturnal Labs seeks to provide the financing, relationships, expertise and guidance needed to build highly successful companies.
Founder & Chairman
Aldo brings 30+ years of experience in investment banking and private equity, with senior positions at leading financial institutions in Milan and London (BNP Paribas, Candover, Merrill Lynch, Deutsche Bank and Credit Agricole Indosuez). Over the years he has successfully invested in several Med-Tech start-ups (Cephea, Triflo, Orthosensor, R3, Aquyre, Memic), thus building a solid network of investors and entrepreneurs across Europe, US and the Middle East. Aldo holds a Degree in business administration from Bocconi University and master degree in Finance from the London Business School. He is FSA approved.
Luigi brings 30+ years in R&D in large pharmaceutical companies with executive positions (Marion Merrell Dow, Hoechst Marion Roussell, Boeringer Ingelheim, Biosearch Italia, Serono, Merck Group); in 1996 Luigi co-founded Biosearch Italia, an Italian biotech company listed at the Nuovo Mercato, which was eventually merged with Versicor, went public on the Nasdaq (changing its name in Vicuron Pharmaceuticals Inc.), and was acquired by Pfizer in 2005 for about 2 billions USD. Luigi holds a degree in Chemistry and Pharmaceutical Technologies, he’s Adjunct Professor at the Department of Drug Pharmaceutical Science of the University of Milan (Italy), and author of 4 patents and several peer reviewed publications.
Founder & Director
Alessandro is currently co-founder and Managing Director of TechWald SpA. Is a senior executive with extensive international experience in leadership and board positions in public and private healthcare and medical technology companies. https://www.linkedin.com/in/alessandro-piga-0066758/
GINO DEL BON
GINO DEL BON
He is currently sole director of GDB Investimenti, a company that invests in production companies operating in various product sectors and organises Club Deals. From 1990 to 2018 he was chairman and CEO of Bruni Glass SpA, one of the world's leading distributors of high-end glass containers for the spirits, gourmet and food markets. A law graduate, he began his entrepreneurial journey at the end of the 1970s when, after an experience as general manager in Vetrerie Bruni Srl, active in the marketing of glass containers for food and pharmaceutical products, he took over its ownership. From the very beginning of his management he started a policy of acquisitions and consolidation of the company's presence in Italy and abroad, particularly in the United States. He holds positions on the Boards of several subsidiaries and is Chairman of Osar spa in Robassomero, Turin - Italy.
Leonardo brings over 30 years of experience as an entrepreneur in the international trading of APIs (Active Pharmaceuticals Ingredients) with specific experience in the antibiotics and cephalosporins sector with a focus on the markets of China and India. He sold the business in 2019 to a large multinational distribution company. Leonardo has a secondary education in the field of chemical experts.
Enterprises with the agility of a small company and the perspective of a multinational
Industry Venture Capital in MedTech Global Innovation
• Operational Holding Company scouting and supporting high growth early stage companies focused on healthcare innovation. • Key strategic focus on MedTech and Pharma Technologies to provide benefit and value for patients, doctors and healthcare systems, while rewarding the shareholders with a sound and ethical profit. • Founded in 2017 by 3 seasoned former executives of MedTech multinationals, with the aim of supporting the development of early stage MedTech companies across Israel and Europe. • So far, invested in 8 companies across Israel, US and EU. • Based in Milan and Tel Aviv
Turnkey product development partner
• Nocturnal Product Development is a privately owned complete, turnkey medical device development company. • Nocturnal’s team members individually possess decades of Class II, and Class III, and - implantable, life - saving product development experience and have worked together for 15 years. • The team is co-located in Durham, NC, in a 4,300 sqf facility incorporating a world-class engineering lab and workspace. Nocturnal operates under an ISO 13485:2016 quality system certified by BSI for development and manufacturing of life saving medical devices.